Background/aim: MEK inhibitors are new promising anticancer drugs. The aim of this study was to investigate the effect of the combination treatment of voreloxin with the MEK inhibitor TAK-733 on HL60 myeloid leukemia cells.

Materials And Methods: MAPK activity, cell viability, apoptosis, oxidative stress induction and AIF (apoptosis-inducing factor) distribution were assessed in HL60 cells cultured with each drug alone or with both drugs.

Results: TAK-733 alone at 5 μM significantly reduced MAPK activity and did not influence viability and apoptosis in HL60 cells. Voreloxin at concentration of 0.03-0.48 μM reduced cell viability and increased apoptosis rate. Incubation with both drugs caused further inhibition of cell viability and increased apoptosis associated with generation of reactive oxygen species (ROS) and nuclear translocation of AIF.

Conclusion: Combination of TAK-733 and voreloxin can exert a synergistic anticancer effect in myeloid leukemia cells.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12967DOI Listing

Publication Analysis

Top Keywords

myeloid leukemia
12
cell viability
12
mek inhibitor
8
leukemia cells
8
mapk activity
8
viability apoptosis
8
hl60 cells
8
μm reduced
8
viability increased
8
increased apoptosis
8

Similar Publications

CD56 CD16 cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.

Front Immunol

January 2025

Team Immunity and Cancer, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Paoli-Calmettes Institute, University of Aix-Marseille UM105, Marseille, France.

Introduction: Acute myeloid leukemia (AML) is a rare haematological cancer with poor 5-years overall survival (OS) and high relapse rate. Leukemic cells are sensitive to Natural Killer (NK) cell mediated killing. However, NK cells are highly impaired in AML, which promote AML immune escape from NK cell immune surveillance.

View Article and Find Full Text PDF

Background: This study aims to identify the hub genes and immune-related pathways in acute myeloid leukemia (AML) to provide new theories for immunotherapy.

Methods: We use bioinformatics methods to find and verify the hub gene. At the same time, we use the results of GSEA enrichment analysis to find immune-related mediators.

View Article and Find Full Text PDF

Neutrophil elastase () mutations are the most common cause of cyclic (CyN) and congenital neutropenia (SCN), two autosomal dominant disorders causing recurrent infections due to impaired neutrophil production. Granulocyte colony-stimulating factor (G-CSF) corrects neutropenia but has adverse effects, including bone pain and in some cases, an increased risk of myelodysplasia (MDS) and acute myeloid leukemia (AML). Hematopoietic stem cell transplantation is an alternative but is limited by its complications and donor availability.

View Article and Find Full Text PDF

Corrigendum: Dogs with acute myeloid leukemia have clonal rearrangements in T and B cell receptors.

Front Vet Sci

January 2025

Animal Health Diagnostic Center, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.

[This corrects the article DOI: 10.3389/fvets.2017.

View Article and Find Full Text PDF

Spontaneous Splenic Rupture Leading to the Diagnosis of CML.

J Community Hosp Intern Med Perspect

January 2025

Department of Internal Medicine, Temple University Health System, Philadelphia, PA, USA.

Background: Spontaneous splenic rupture (SSR) is a known complication of hematologic malignancy. Rare cases have been reported in which patients presented with SSR prior to diagnosis of chronic myeloid leukemia (CML). We present a case of atraumatic SSR due to CML presenting as persistent abdominal pain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!